Full history for every metric is available with a Kvantra account
HOOKIPA Pharma Inc. (HOOK)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 20 | 18 | 14 | 20 | 44 | 10 | 15 |
| Operating profit | $m | -37 | -65 | |||||
| Net profit | $m | -44 | -76 | -65 | -82 | -44 | -14 | -56 |
| EPS reported | $ | -1.09 | -4.72 | |||||
| Operating cashflow per share | $ | -0.91 | -0.56 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.91 | -0.56 | |||||
| Free cash flow | $m | -12 | -46 | |||||
| Net debt | $m | -37 | -34 | |||||
| Book value equity | $m | 33 | 29 | |||||
| Book value per share | $ | 2.57 | 2.26 | |||||
| Number of shares | m | 12.65 | 12.68 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.35 | 0.50 | |||||
| P/S LTM | x | 1.16 | 0.97 | |||||
| P/FCF LTM | x | -0.98 | -0.32 | |||||
| EV/EBITDA LTM | x | 0.72 | 0.37 | |||||
| EV/Sales LTM | x | -2.68 | -1.34 | |||||
| Earnings Yield LTM | % | -122.50% | -118.02% | |||||
| FCF Yield | % | -102.00% | -316.62% | |||||
| Quality | ||||||||
| ROE | % | -42.55% | -54.85% | |||||
| ROIC | % | -103.25% | -61.68% | |||||
| Operating margin | % | -376.99% | -278.95% | |||||
| Gross margin | % | 92.97% | 100.00% | |||||
| FCF/Sales | % | -118.76% | -80.70% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -77.93% | -71.52% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -85.34 | -83.48 | |||||
| Net Debt/EBITDA | x | 1.04 | 2.06 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -330.11% | -237.78% | |||||
| Net debt/Equity | x | -1.15 | -1.19 | |||||
| Gross debt/equity | x | 0.00 | 0.02 | |||||
Company overview
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free